Abstract
Rapid improvement in glycaemic control with GLP-1 receptor agonist (RA) therapy has been reported to be associated with significant progression of diabetic retinopathy. This deterioration is transient, and continuing GLP-1 RA treatment is associated with reversal of this phenomenon. Pre-existent maculopathy, higher grade of retinopathy and longer duration of diabetes may be risk factors for persistent deterioration.
Keywords:
GLP-1 agonist; Retinopathy; Screening; Transient deterioration.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.
MeSH terms
-
Blood Glucose / metabolism*
-
Diabetes Mellitus, Type 2 / complications*
-
Diabetes Mellitus, Type 2 / prevention & control
-
Diabetic Retinopathy / blood
-
Diabetic Retinopathy / drug therapy*
-
Disease Progression
-
Exenatide
-
Follow-Up Studies
-
Glucagon-Like Peptide 1 / metabolism
-
Glucagon-Like Peptide-1 Receptor
-
Glycated Hemoglobin / metabolism
-
Humans
-
Hypoglycemic Agents / therapeutic use*
-
Middle Aged
-
Peptides / therapeutic use*
-
Receptors, Glucagon / agonists*
-
Risk Factors
-
Venoms / therapeutic use*
Substances
-
Blood Glucose
-
GLP1R protein, human
-
Glucagon-Like Peptide-1 Receptor
-
Glycated Hemoglobin A
-
Hypoglycemic Agents
-
Peptides
-
Receptors, Glucagon
-
Venoms
-
hemoglobin A1c protein, human
-
Glucagon-Like Peptide 1
-
Exenatide